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Poliovirus was first isolated nearly 100 years ago in a landmark experiment that established the viral etiology of poliomyelitis. This discovery
stimulated investigation of the pathogenesis of poliomyelitis in many laboratories. Nearly 50 years later, when two effective poliovirus vaccines
were developed, the impetus to study poliovirus pathogenesis waned. The identification of the cell receptor for poliovirus, CD155, and its use in
the development of transgenic mice susceptible to poliovirus revived interest in understanding how the virus causes disease. Experiments in
CD155 transgenic mice have provided new information on the initial sites of virus replication in the host, how the virus spreads to the central
nervous system through the blood and by axonal transport, the determinants of viral tropism, and the basis for the attenuation phenotype of the
Sabin vaccine strains. Despite these advances, our understanding of poliovirus pathogenesis is still incomplete. The dilemma is not how to answer
the remaining questions, but whether there will be sufficient time to do so before global eradication of poliomyelitis leads to cessation of research
on the disease.
D 2005 Elsevier Inc. All rights reserved.
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Near the beginning of the 20th century epidemics of the
acute central nervous system disease known as poliomyelitis
began to occur in the United States and Europe. These
outbreaks came as a surprise to the medical community, which
viewed the disease as a rarity. The causative agent of this
disease, poliomyelitis virus (later shortened to poliovirus) was0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.09.015
* Fax: +1 212 305 5106.
E-mail address: vrr1@columbia.edu.identified in 1908 (Landsteiner and Popper, 1908). Research on
the virus over the next 40 years provided information on
antigenic types, pathogenesis, and immunity that ultimately
lead to the development of two effective vaccines. A
consequence of the introduction of these vaccines in the early
1960s was that investigation of the pathogenesis of poliomy-
elitis ceased. Instead, studies on the molecular biology,
structure, and genetics of poliovirus flourished. The identifi-
cation of the cell receptor for poliovirus allowed the
development of transgenic mice susceptible to poliovirus, an
advance that revived interest in understanding how the virus006) 9 – 16
www.e
V.R. Racaniello / Virology 344 (2006) 9–1610causes disease (Koike et al., 1991; Ren et al., 1990). Work on
poliovirus pathogenesis is now done with a sense of urgency as
global eradication of polio approaches.
Poliovirus is classified as an enterovirus within the
Picornaviridae, a family that contains many human and animal
pathogens. All three serotypes of poliovirus cause paralytic
disease. The viral genome, a single-stranded, (+)-strand RNA
approximately 7500 nucleotides in length, is enclosed in a
nonenveloped capsid comprising 60 copies of four different
polypeptides arranged with icosahedral symmetry. The cell
receptor for all three poliovirus serotypes is CD155, a
glycoprotein that is a member of the immunoglobulin
superfamily of proteins (Mendelsohn et al., 1989). CD155 is
composed of three extracellular immunoglobulin-like domains:
a membrane-distal V-type domain that binds poliovirus,
followed by two C2-type domains. Alternative splicing of
mRNA leads to the synthesis of two membrane-bound
isoforms, CD155a and CD155y, and two isoforms that lack
transmembrane domains and are secreted from the cell (Koike
et al., 1990; Mendelsohn et al., 1989). The function of the
secreted isoforms is unknown. The membrane bound isoforms
are adhesion molecules: they participate in the formation of
adherens junctions through interaction with nectin-3, an
immunoglobulin-like protein related to CD155 (Mueller and
Wimmer, 2003). CD155 is also a recognition molecule for
natural killer (NK) cells; it interacts with CD226 and CD96 on
NK cells to stimulate their cytotoxic activity (Bottino et al.,
2003; Fuchs et al., 2004). The UL141 protein of cytomegalo-
virus blocks surface expression of CD155, leading to evasionFig. 1. Hypothetical scheme of poliovirus pathogenesis based on experimental find
virus initially replicates in the oropharyngeal and intestinal mucosa. Virus replication
viremia. Invasion of virus into the central nervous system may occur either dire
neuromuscular junction. It is believed that invasion of the brain or spinal cord mu
sustained viremia. These extraneural tissues may include skeletal muscle and brown
from the nasopharynx may lead to transmission of infection by the respiratory routof NK cell-mediated killing (Tomasec et al., 2005). CD155 and
related proteins also serve as entry receptors for alphaherpes-
viruses (Spear, 2004).
Interaction of poliovirus with the V-type domain 1 of
CD155 leads to a conformational change in the virus particle
and release of the RNA genome into the cytoplasm, an event
that may occur at the plasma membrane in cultured cells
(Hogle, 2002). Once in the cytoplasm, the viral RNA genome
is translated and the production of new infectious virions
begins, a process that has been recently discussed (Mueller et
al., 2005; Racaniello, 2001).
Course of poliovirus infection
Infection with poliovirus begins when the virus is ingested
and multiplies in the oropharyngeal and intestinal mucosa (Fig.
1) (Bodian and Horstmann, 1965; Sabin, 1956). Virus shed in
the feces of infected individuals is largely responsible for
transmission of infection. From the primary sites of multipli-
cation in the mucosa, virus drains into cervical and mesenteric
lymph nodes and then to the blood, causing a transient viremia
(Bodian and Horstmann, 1965). Most natural infections of
humans end at this stage with a minor disease comprising
nonspecific symptoms such as sore throat, fever, and malaise.
Replication at extraneural sites is believed to maintain viremia
beyond the first stage and increase the likelihood of virus entry
into the central nervous system. Such extraneural sites might
include brown fat, reticuloendothelial tissues, and muscle
(Bodian, 1955; Ren and Racaniello, 1992a; Wenner andings in humans, monkeys, chimpanzees, and CD155 transgenic mice. Ingested
at these sites reaches the blood through the lymph nodes, resulting in a primary
ctly from the blood, or by retrograde axonal transport when virus enters the
st be preceded by viral multiplication in extraneural tissues, which leads to a
fat. Virus is spread most frequently by the fecal–oral route. Shedding of virus
e, which occurs in developed countries with high standards of sanitation.
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enters the central nervous system and replicates in motor
neurons within the spinal cord, brain stem, or motor cortex.
Viral replication in motor neurons within the spinal cord leads
to the characteristic muscle paralysis.
Because only 1–2% of poliovirus infections lead to
poliomyelitis, the neurological phase of infection can be
viewed as an accidental diversion of the enteric stage. Spread
of poliovirus within the population, and therefore survival of
the virus, depends only on viral multiplication in the alimentary
tract. Why poliovirus only rarely invades the central nervous
system is not known, but a possible explanation is discussed
below (see FTropism_).
Host range
Humans are the only known natural hosts of poliovirus.
Chimpanzees and old world monkeys such as rhesus,
cynomolgous, and African green monkeys can be experimen-
tally infected. The results of experiments in mice suggested that
the resistance of other species to infection by poliovirus is
likely due to the absence of a suitable cell receptor. Cultured
mouse cells are not susceptible to poliovirus infection, but they
are permissive, e.g. they produce infectious virus after
transfection with viral RNA (Holland et al., 1959a, 1959b).
The synthesis of CD155 in mouse L cells or in transgenic mice
confers susceptibility to infection (Koike et al., 1991;
Mendelsohn et al., 1989; Ren et al., 1990). Orthologs of the
CD155 gene are present in the genomes of a number of
mammals, including those that are not susceptible to poliovirus
infection (Ida-Hosonuma et al., 2003). The amino acid
sequence of domain 1 of CD155, which contains the binding
site for poliovirus, varies extensively among the nonsusceptible
mammals, especially in the regions known to contact poliovi-
rus. The absence of a poliovirus binding site on these CD155
molecules therefore explains why poliovirus infection is
restricted to simians.
Certain strains of poliovirus can infect mice in the absence
of human CD155. The strains P2/Lansing, P1/Lsb, and a
variant of P3/Leon were selected for replication in mice by a
process of adaptation involving serial passage of viruses in
nonprimates (Armstrong, 1939; Li and Schaeffer, 1953). Other
poliovirus strains are naturally virulent in mice (Moss and
Racaniello, 1991). When mice are inoculated intracerebrally
with P2/Lansing, they develop a disease with clinical,
histopathological, and age-dependent features that resembles
human poliomyelitis (Ford et al., 2002; Jubelt et al., 1980a,
1980b). The murine cell receptor that allows entry of these
strains into mouse cells has not been identified. Substitution of
a six amino acid sequence of the P1/Mahoney strain with the
corresponding sequence from P2/Lansing confers mouse
neurovirulence to the recombinant virus (Murray et al.,
1988). This six amino acid sequence lies within capsid protein
VP1, on the surface of the virion at the five-fold axis of
symmetry (Lentz et al., 1997), near the binding site for CD155
(Belnap et al., 2000; He et al., 2000; Xing et al., 2000). These
observations suggest that the six amino acid sequence in thecapsid of P2/Lansing regulates the interaction with a mouse
cell receptor, possibly by direct contact.
Entry into the host
Whether epithelial or lymphoid cells are the primary sites of
poliovirus replication in the oropharyngeal and intestinal
mucosa has been a matter of debate for many years. Virus
has been detected in tonsillopharyngeal tissue and Peyer’s
patches of chimpanzees that had been orally infected with
poliovirus (Bodian and Horstmann, 1965). In humans, polio-
virus has been isolated from tonsillopharyngeal tissue, the wall
of the ileum, and mesenteric lymph nodes (Sabin and Ward,
1941). However, removal of tonsils or adenoids does not
reduce the level of poliovirus multiplication in the throats of
humans (Sabin, 1956). Consequently, it is not known if
poliovirus replicates in lymphoid tissues or is absorbed into
lymph nodes after replication in epithelial cells.
Studies on the expression of CD155 in cells of the
alimentary tract have been used to provide information on
which cell types might be susceptible to infection. Human
epithelial cells produce high levels of CD155 RNA, suggesting
that these cells might be primary sites of poliovirus replication
(Ren, 1992). In humans, CD155 protein was detected on the
intestinal epithelium, M cells of Peyer’s patches, and in
germinal centers within the Peyer’s patches (Iwasaki et al.,
2002). In rhesus macaques, which are not susceptible to oral
poliovirus infection, CD155 levels were reduced in follicle-
associated epithelium and the protein was not present in
germinal centers. These results have been interpreted to suggest
that poliovirus replication in the gut depends on the presence of
CD155 in follicle-associated epithelium, including M cells, and
on cells of the Peyer’s patches (Iwasaki et al., 2002).
CD155 transgenic mice are not susceptible to oral infection
with poliovirus (Koike et al., 1991; Ren et al., 1990). CD155
protein is present at very low levels in the intestinal epithelium
of these mice, and absent in the Peyer’s patches (Iwasaki et al.,
2002; Zhang and Racaniello, 1997). Overproduction of CD155
in the intestinal epithelium of transgenic mice by the use of a
fatty acid binding protein promoter did not lead to oral
susceptibility to poliovirus (Zhang and Racaniello, 1997).
These findings suggest that the expression of CD155 in Peyer’s
patches and in M cells is important for oral susceptibility to
poliovirus infection. However, these data do not exclude the
possibility that poliovirus might also replicate in the intestinal
epithelium. In the mouse intestine, these cells might not be
permissive for poliovirus infection due to the absence of an
intracellular protein required for viral replication. The produc-
tion of CD155 transgenic mice that express the poliovirus
receptor in Peyer’s patches and M cells should resolve these
questions. A line of transgenic mice (cPvr mice) has been
described in which production of CD155 mRNA is under the
control of the h-actin promoter (Crotty et al., 2002). The use of
this promoter is expected to result in expression of transgene
mRNA in all cells, although CD155 synthesis in individual cell
types in the intestine was not examined. Unfortunately, cPvr
mice do not develop paralytic disease after oral inoculation
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poliovirus replication were detected in the intestine, but the
cells harboring poliovirus were not identified. Additional work
is needed to determine the block to poliovirus replication in
different CD155 transgenic mouse lines.
Although CD155 transgenic mice cannot be orally infected
with poliovirus, inoculation by the intranasal route leads to
paralysis accompanied by virus replication in the nasal
epithelium and olfactory bulb, cerebrum, brain stem, and
spinal cord (Crotty et al., 2002; Nagata et al., 2004). The nasal
route of infection does not appear to play a significant role in
human poliomyelitis. Early hypotheses on the pathogenesis of
poliomyelitis suggested that the virus entered the nose,
replicated in the nasal epithelium, and spread to the brain by
the olfactory pathway (Paul, 1971). Experimental findings in
humans and monkeys subsequently proved that poliovirus does
not invade the central nervous system by the olfactory route
(Sabin and Ward, 1941). It is possible that in some cases, viral
replication in the nasal mucosa leads to a viremia that allows
virus to spread and eventually gain entry into the central
nervous system. Although poliovirus is believed to be
transmitted by fecal–oral contamination, in countries with
high standards of hygiene, virus may be transmitted by the
respiratory route. The source of virus for this mode of
transmission is the tonsils and pharynx. Replication at these
sites usually occurs after virus replication in the intestine and
spread by viremia. When infection is spread by the respiratory
route, it is not clear if virus replicates in the nasopharynx, or is
ingested and replicates in the intestine. The study of nasal
infection of CD155 transgenic mice with poliovirus may
therefore have some relevance to human infections.
Spread in the host
Two routes of poliovirus entry into the central nervous
system have been suggested which are not mutually exclusive:
the virus enters the central nervous system from the blood, or
enters a peripheral nerve and is carried to the central nervous
system by axonal transport. There is ample evidence in support
of both routes of entry. It has been established that viremia
preceding paralytic infection is necessary for virus entry into
the central nervous system. In addition, the presence of
antiviral antibodies in the blood prevents invasion of the brain
and spinal cord (Bodian and Horstmann, 1965). The results of
experiments in CD155 transgenic mice have provided addi-
tional support for the hypothesis that virus enters the brain and
spinal cord from the blood. In one study, the fate of poliovirus
inoculated into the tail vein of mice was examined by
pharmacokinetic analysis (Yang et al., 1997). The results
indicate that poliovirus is delivered to the brain in amounts
significantly greater than would be predicted from the vascular
volume of that organ. Furthermore, the distribution of
poliovirus in the brain of transgenic and nontransgenic mice
is similar, indicating that CD155 does not play a role in
delivery of circulating poliovirus to the central nervous system.
The authors conclude that, in mice, polioviruses permeate the
blood–brain barrier at a high rate, independent of CD155 orvirus strain. The molecular mechanism of poliovirus entry by
this route remains to be elucidated.
Substantial evidence for neural pathways of poliovirus
dissemination has been obtained in humans and monkeys.
Inoculation of poliovirus into the sciatic nerve of monkeys
leads to virus spread along nerve fibers in both peripheral
nerves and the spinal cord (Hurst, 1936). When monkeys are
inoculated intramuscularly with poliovirus, the inoculated limb
is usually the first to become paralyzed, and freezing the
sciatic nerve blocks virus spread to the spinal cord (Nathanson
and Bodian, 1961). In children who received incompletely
inactivated poliovaccine in 1954 (the Cutter incident), a high
frequency of initial paralysis was observed in the inoculated
limb (Nathanson and Langmuir, 1963). Evidence for neuronal
spread of poliovirus has also been obtained from experiments
in CD155 transgenic mice. After intramuscular inoculation of
CD155 transgenic mice, the first limb paralyzed is always the
limb that is inoculated; poliovirus is first detected in the lower
spinal cord, and sciatic nerve transection blocks infection of
the spinal cord (Ohka et al., 1998; Ren and Racaniello,
1992b). The rate of poliovirus transport along the sciatic nerve
was calculated to exceed 12 cm per day, independent of virus
replication (Ohka et al., 1998). Therefore, poliovirus is carried
along nerves to the spinal cord by fast retrograde axonal
transport.
Skeletal muscle injury is known to be a predisposing factor
for poliomyelitis, a phenomenon known as Fprovocation
poliomyelitis_. For example, in Rumania, intramuscular injec-
tions have been linked to cases of vaccine-associated polio-
myelitis (Sutter et al., 1992). Provocation poliomyelitis has
been reproduced in CD155 transgenic mice (Gromeier and
Wimmer, 1998). The mechanism by which skeletal muscle
injury stimulates retrograde axonal transport of poliovirus to
the spinal cord remains to be determined.
Clues about the mechanism by which poliovirus is
conveyed by neural pathways are provided by the observation
that the cytoplasmic domain of CD155 interacts with Tctex-1,
the light chain of the retrograde motor complex dynein
(Mueller et al., 2002; Ohka et al., 2004). This finding suggests
the following hypothesis for axonal transport of poliovirus. At
the interface of muscle and motor neuron, known as the
neuromuscular junction, poliovirus binds CD155 and is taken
into the neuron by endocytosis. In support of this model,
CD155 has been detected at the neuromuscular junction of
human muscle (Leon-Monzon et al., 1995). The endocytic
vesicles containing poliovirus are linked to Tctex-1 by the
cytoplasmic domain of CD155, which remains on the exterior
of the vesicle. The virus-containing vesicles are transported to
the motor neuron cell body, where the viral RNA is released
into the cytoplasm and virus replication begins. Experimental
evidence has been obtained which demonstrates that poliovi-
rus-containing vesicles are brought to the spinal cord by axonal
transport dependent upon Tctex-1 (Ohka et al., 2004).
Furthermore, poliovirus appears to be transported in axonal
endosomes as an infectious, 160S particle. This process differs
from virus entry in HeLa cells, where interaction of poliovirus
with CD155 leads to conversion of the virus to 135S particles,
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Hogle, 1990). Suppression of viral uncoating in axons may be
mediated by a specific mechanism to avoid degradation of viral
RNA before it can reach the cell body for translation.
Uptake of poliovirus at the neuromuscular junction also
differs from the process in HeLa cells, where infection does not
require dynamin and is unlikely to involve the clathrin-mediated
endocytic pathway (DeTulleo and Kirchhausen, 1998).
Tropism
In the primate host, poliovirus infection is localized to
specific cells and tissues, despite the presence of virus in many
organs during the viremic phase (Bodian, 1955; Sabin, 1956).
For many years, it was believed that poliovirus tropism was
determined by the cellular receptor. This hypothesis was
supported by the finding that virus binding activity in tissue
homogenates correlated with susceptibility to poliovirus
infection (Holland, 1961). The identification of the poliovirus
receptor enabled a more extensive study of the role of receptor
in poliovirus tropism. In humans, CD155 RNA and protein are
expressed in a wide range of tissues, including those that are
not sites of poliovirus infection (Freistadt et al., 1990; Koike et
al., 1990; Mendelsohn et al., 1989). CD155 RNA and protein
expression are also observed in many tissues of CD155
transgenic mice, including those where poliovirus does not
replicate (Koike et al., 1994; Ren and Racaniello, 1992a).
These findings lead to the conclusion that CD155 is required
for susceptibility to poliovirus infection, but tropism is
determined at a later stage of infection.
It has also been suggested that poliovirus tropism is
determined by cell-type-specific differences in translation
mediated by the viral internal ribosome entry site (IRES)
(Borman et al., 1997; Gromeier et al., 1996; Ohka and Nomoto,
2001; Yanagiya et al., 2003). Cell proteins in addition to
canonical translation initiation proteins have been identified
that influence IRES-mediated translation (Belsham and Sonen-
berg, 2000). Organ-specific synthesis, localization, or modifi-
cation of these proteins could lead to regulation of viral
replication. In support of this hypothesis, recombinant polio-
viruses dependent upon the IRES of human rhinovirus type 2
or hepatitis C virus do not replicate or cause disease in the
spinal cord of CD155 transgenic mice (Gromeier et al., 1996;
Lu and Wimmer, 1996; Yanagiya et al., 2003). When
recombinant adenoviruses were used to express bicistronic
mRNAs in murine organs, the IRES of poliovirus was found to
mediate translation in many organs, including those that are not
sites of poliovirus replication (Kauder and Racaniello, 2004).
Recombinant poliovirus dependent upon the IRES of hepatitis
C virus replicated in the central nervous system, and caused
paralysis in newborn CD155 transgenic mice. Previous failure
to observe paralysis in mice inoculated with poliovirus
dependent upon the IRES of hepatitis C virus was likely a
consequence of poor replication of the recombinant virus,
leading to clearance from adult mice. These results indicate that
poliovirus tropism is not determined by internal ribosome
entry, but at a later stage in replication.The innate immune system, which can respond to the
presence of virus within hours, can have a major influence on
the outcome of infection. For example, the tropism of several
viruses is regulated by alpha/beta interferon (IFNa/h) (Garcia-
Sastre et al., 1998; Ryman et al., 2000). Based on this
observation, the effect of the IFNa/h response on the tropism
of poliovirus was determined (Ida-Hosonuma et al., 2005).
Poliovirus infection of CD155 transgenic mice lacking the
receptor for IFNa/h resulted in viral replication in liver, spleen,
and pancreas, in addition to the central nervous system. CD155
is produced in all of these tissues, but poliovirus only replicates
in the brain and spinal cord of CD155 transgenic mice that
synthesize the IFNa/h receptor. In CD155 transgenic mice,
poliovirus infection leads to a rapid and robust expression of
IFN-stimulated genes (ISGs) (oligoadenylate synthetase, PKR,
IFNa, RIG-I, MDA-5 and IRF-7) in extraneural tissues that are
not normally sites of poliovirus replication. In contrast, ISG
expression in the brain and spinal cord was only moderately
increased after infection. These results indicate that IFNa/h
functions as an important determinant of poliovirus tissue
tropism in CD155 transgenic mice by protecting extraneural
organs from infection.
The identification of IFNa/h as a determinant of poliovirus
tissue tropism invites speculation on several aspects of
poliovirus pathogenesis. As discussed earlier, poliovirus
replication at the entry portal leads to a viremia, which allows
virus to reach an unidentified extraneural site. Replication at
this site appears to be required for virus entry into the central
nervous system. We speculate that, in 99% of infections, the
IFNa/h response limits poliovirus replication in extraneural
tissues, thereby preventing invasion of the central nervous
system. In the 1–2% of individuals in which paralytic disease
occurs, the IFN response may be defective, allowing robust
virus replication in nonneural sites followed by invasion into
the central nervous system. It will be interesting to determine
whether individuals who contract poliomyelitis have defects in
innate responses to infection.
The observation that poliovirus replication in nonneural
tissues of CD155 transgenic mice is limited by the IFNa/h
response is surprising in light of the changes wrought by
poliovirus infection on the host cell. Poliovirus infection leads
to inhibition of host cap-dependent translation, DNA-depen-
dent RNA synthesis, cellular protein secretion (including
elaboration of cytokines and antigen presentation), nuclear
export, and suppression of the NF-nB response (Neznanov et
al., 2005). Given these effects, it is difficult to imagine that
infection would be limited by IFNa/h, whose effects require
many of the cellular activities inhibited by virus infection.
Furthermore, poliovirus replication in cultured cells appears to
be relatively resistant to IFNa (unpublished results). This
apparent paradox might be a consequence of the fact that most
experiments in cell culture are carried out at higher multiplic-
ities of infection than those which occur in animals during virus
infection. At lower multiplicities of infection likely to be
present in tissues, the effects of virus replication on cellular
processes might be significantly dampened, rendering replica-
tion sensitive to IFNa/h.
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The effort to eradicate global poliomyelitis has been
conducted through the widespread use of live, attenuated
poliovirus vaccines produced by Sabin. These vaccine strains
infect the alimentary tract and produce immunity to infection
(Sabin et al., 1954). Genetic analysis has shown that a point
mutation within the IRES of each of the three poliovirus
vaccine strains is a determinant of the attenuation phenotype
(Evans et al., 1985; Kawamura et al., 1989; Ren et al., 1991).
For example, a mutation from C to U at nucleotide 472 in the
IRES of poliovirus type 3 attenuates neurovirulence in primate
and murine models (Evans et al., 1985; La Monica et al., 1987;
Westrop et al., 1989). This mutation has been shown to cause a
translation defect in vitro and in cultured cells of neuronal
origin (Gutierrez-Escolano et al., 1987; Haller et al., 1996;
Svitkin et al., 1990). It has been suggested that the C472U
mutation causes a translation defect that is specific to the brain
and spinal cord and leads to lower viral replication in these
organs (Gutierrez-Escolano et al., 1987; La Monica and
Racaniello, 1989; Ohka and Nomoto, 2001). Reduced replica-
tion in the brain and spinal cord could explain the attenuated
neurovirulence of the poliovirus vaccine strains.
To test this hypothesis, IRES-mediated translation was
examined in mouse organs and cells. The C472U mutation
was found to cause identical translation defects in neuronal and
nonneuronal cells and tissues (Kauder and Racaniello, 2004).
The C472U mutation therefore does not lead to attenuation of
neurovirulence by specifically reducing translation in neuronal
cells. Furthermore, it was found that polioviruses with the
C472U mutation, which are attenuated in adult CD155
transgenic mice, replicate in newborn mice and cause paralytic
disease (Kauder and Racaniello, 2004). Therefore, the C472U
mutation does not eliminate viral replication in the brain.
Rather, the C472U mutation might reduce viral replication
sufficiently in the alimentary tract to prevent spread to the
central nervous system without impairing immunogenicity of
the vaccine. The reduced replication of the vaccine strains may
allow the IFNa/h response to more effectively limit viral
replication than it does in infections with wild type virus.
Immunization with the Sabin vaccine strains is associated
with a low rate of vaccine-associated poliomyelitis, either in
vaccine recipients or their immediate contacts. The rate of
vaccine-associated paralysis in primary vaccines is 1 per
750,000 recipients (Nkowane et al., 1987). Vaccine-associated
poliomyelitis occurs due to reversion of the mutations in the
viral genome that confer the attenuation phenotype. For
example, a reversion from U to C at nucleotide 472 is observed
in virus isolated from cases of vaccine-associated poliomyelitis
caused by Sabin type 3 (Evans et al., 1985). Such reversion
events appear to occur in the gastrointestinal tract of most
individuals immunized with the Sabin vaccine strains (Marti-
nez et al., 2004). It is therefore puzzling why the Sabin vaccine
causes vaccine associated disease in so few recipients. One
possible explanation is that, even with selection of revertants in
the alimentary tract, the replication of the Sabin strains is still
sufficiently delayed in most hosts to allow containment by theimmune response. Perhaps those few unfortunate individuals
who contract vaccine-associated poliomyelitis have a defective
IFNa/hresponse that allows revertant viruses to multiply
unchecked in extraneural tissues, eventually invading the
central nervous system and causing paralytic disease.
Conclusions and future perspectives
The identification of the cell receptor for poliovirus and its
use in the development of transgenic mouse models for
poliovirus infection has provided new impetus for understand-
ing how poliovirus causes disease. Findings in CD155
transgenic mice have provided some answers while spawning
many new questions. The identity of cells that are initially
infected by poliovirus in the alimentary tract remains to be
determined. To address this question, it will be necessary to
determine why the intestinal tract of CD155 transgenic mice is
resistant to poliovirus infection. If an orally susceptible mouse
line is developed, it could be used to study the precise route of
virus spread from the intestine to the central nervous system.
How does the virus enter the blood? Does virus travel from the
intestine to the brain stem via the vagus nerve, as does reovirus
in mice? (Morrison et al., 1991). What is the mechanism of
poliovirus axonal transport, what are the factors that maintain
virus as 160S particles in endosome, and what is the trigger for
uncoating in the neuron cell body?
The involvement of the IFNa/h response in poliovirus
tropism leads to a host of questions about the role of innate
responses in infection. In CD155 transgenic mice, the IFNa/h
response appears to dampen virus replication in nonneural
tissues due to a robust induction of ISG expression. Why is
ISG expression limited in the central nervous system? What are
the roles of the individual sensors of the innate response –
RIG-I, MDA-5, TLR3, and TLR7/8 – in poliovirus infection,
and do these roles differ in neural and nonneural organs?
Poliovirus is known to inhibit many important cellular
processes, including translation, transcription, and protein
secretion. Why then is poliovirus replication in mice regulated
by IFNa/h? Why is poliovirus infection of CD155 transgenic
mice accompanied by significant inflammation, in light of the
effects of infection on cellular macromolecular synthesis and
protein secretion? What is the role of the innate and adaptive
responses in the destruction of neurons?
The eradication of poliomyelitis has been an enormous
success, and while setbacks in the program occur with regular
frequency, the effort is expected to eventually succeed.
Shortly after this goal is attained, it will be necessary to halt
work with virulent strains of poliovirus, a step that will
severely curtain research on the pathogenesis of poliomyelitis.
At the moment, we know more than ever about the
pathogenesis of poliomyelitis, and an enormous array of
experimental tools are available to further advance the field.
The dilemma is not how to answer the remaining questions,
but whether there will be sufficient time to do so. Perhaps we
can make sufficient inroads into the problems outlined here to
establish paradigms that will help us better understand other
virus diseases.
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